Regarding first generation EGFR TKIs, in two recent phase II randomized trials [21, 22], patients with treatment-naive advanced EGFR mutant NSCLC were treated with continuous gefitinib in combination with chemotherapy (pemetrexed in [22] and carboplatin-pemetrexed in [21]). Here, EGFR is linked to non-small cell lung carcinoma.